There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Aravive (ARAV – Research Report), Keros Therapeutics (KROS – Research Report) and Legend Biotech (LEGN – Research Report) with bullish sentiments.
Aravive (ARAV)
In a report released yesterday, Robert Hazlett from BTIG maintained a Buy rating on Aravive, with a price target of $26.00. The company’s shares closed last Wednesday at $0.80, close to its 52-week low of $0.58.
According to TipRanks.com, Hazlett is a 2-star analyst with an average return of
Aravive has an analyst consensus of Moderate Buy, with a price target consensus of $26.00, a 3150.0% upside from current levels. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $26.00 price target.
See the top stocks recommended by analysts >>
Keros Therapeutics (KROS)
BTIG analyst Julian Harrison reiterated a Buy rating on Keros Therapeutics on October 10 and set a price target of $95.00. The company’s shares closed last Wednesday at $42.97.
According to TipRanks.com, Harrison is a 1-star analyst with an average return of
Currently, the analyst consensus on Keros Therapeutics is a Strong Buy with an average price target of $95.00, implying a 124.4% upside from current levels. In a report issued on October 10, Jefferies also reiterated a Buy rating on the stock with a $75.00 price target.
Legend Biotech (LEGN)
BMO Capital analyst Kostas Biliouris reiterated a Buy rating on Legend Biotech today and set a price target of $77.00. The company’s shares closed last Wednesday at $38.83.
According to TipRanks.com, Biliouris is a 3-star analyst with an average return of
Legend Biotech has an analyst consensus of Strong Buy, with a price target consensus of $69.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ARAV:
- Analysts Offer Insights on Materials Companies: Endeavour Silver (EXK) and Osisko Gold Royalties (OR)
- Jim Cramer Says Stocks Will Climb Once Fed Signals Shift; Here Are 2 Names to Watch
- Lucid Up After Q3 Production Update
- BMO Capital Remains a Hold on Hecla Mining Company (HL)
- BTIG Reaffirms Their Hold Rating on DraftKings (DKNG)
